Therapeutic Solutions International with Subsidiary Campbell Neurosciences Develops Cord Blood Based Inhalable Product for Opioid Addiction

Rhea-AI Summary

Therapeutic Solutions International (OTC: TSOI) announced a new patent filing for a cord blood-based intranasal product aimed at reducing adverse mental effects from opioid addiction. Preclinical studies demonstrated its efficacy in suppressing TLR4, a protein linked to opioid addiction, and reducing brain inflammation. The company emphasizes that this innovative approach addresses the root causes of addiction, unlike existing treatments. The development marks a significant step towards potential clinical applications in treating opioid addiction.

Positive

• Successful patent filing for a novel intranasal product targeting opioid addiction.
• Preclinical studies show that the product suppresses TLR4 and reduces brain inflammation.
• The approach addresses root causes of addiction rather than substituting one addiction for another.

Negative

• None.

ELK CITY, Idaho, April 13, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced filing of a patent with new data covering a cord blood based intranasal product demonstrated to reduce adverse mental effects associated with opioid addiction. 

In the series of studies, inflammation was stimulated in the brains of animals using inducers and activators of TLR4, a protein associated with opioid addiction.  Administration of the Company's cord blood based therapeutic resulted in suppression of TLR4 as well as inhibition of inflammation in the brain.

"In recent times numerous publications have reported the link between brain inflammation and opioid addiction¹,²" said Dr. James Veltmeyer, Chief Medical Officer of Campbell Neurosciences. "By combining the regenerative effects of umbilical cord blood, with the anti-inflammatory properties of NanoStilbeneä, together with proprietary neuromodulating agents, we have created a treatment approach which appears to be safe and potently effective in our preclinical studies."

"Campbell Neurosciences is focused not just on identifying suicidal ideations utilizing our clinically validated Campbell Score™ blood-based test, but also on providing possible solutions to prevent suicide," said Kalina O'Connor, President and CEO of Campbell Neurosciences. "The announcement of preclinical success using our cord blood based approach sets the foundation for optimization and development of a clinically-useful approach to treat this dreaded disease."

"Current approaches to drug addiction many times involve replacing one addiction with another one, while not addressing the root cause," said Timothy Dixon, President and CEO of Therapeutic Solutions International, the Parent Company of Campbell Neurosciences and co-inventor of the patent. "We are glad to lend our immunological expertise to Campbell Neurosciences for the development of the world's first immunotherapeutic approach to opioid addiction." 

About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/ 

ir@tsoimail.com

1 Eidson et al. Inflammatory mediators of opioid tolerance: Implications for dependency and addiction. Peptides. 2019 May;115:51-58.
2 Hofford et al. Neuroimmune mechanisms of psychostimulant and opioid use disorders. Eur J Neurosci. 2019 Aug;50(3):2562-2573.

View original content:http://www.prnewswire.com/news-releases/therapeutic-solutions-international-with-subsidiary-campbell-neurosciences-develops-cord-blood-based-inhalable-product-for-opioid-addiction-301267713.html

SOURCE Therapeutic Solutions International

FAQ

What patent has Therapeutic Solutions International filed regarding TSOI?

Therapeutic Solutions International filed a patent for a cord blood-based intranasal product that aims to reduce the adverse mental effects associated with opioid addiction.

What is the significance of the TLR4 protein in relation to TSOI's new product?

The TLR4 protein is associated with opioid addiction, and TSOI's product has shown efficacy in suppressing this protein, which may help mitigate addiction effects.

What are the preclinical results related to TSOI's cord blood-based product?

Preclinical studies indicated that TSOI's cord blood-based therapeutic effectively reduces inflammation in the brain linked to opioid addiction.

How does TSOI's approach to treating opioid addiction differ from existing methods?

TSOI's approach focuses on addressing the root causes of opioid addiction rather than merely replacing one addiction with another.